OCULAR THERAPEUTIX, INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
OCULAR THERAPEUTIX, INC (OCUL) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- OCULAR THERAPEUTIX, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $2.51M.
- OCULAR THERAPEUTIX, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-12-31 was $0.00.
- OCULAR THERAPEUTIX, INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2019-09-30 was $0.00.
- OCULAR THERAPEUTIX, INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $2.04M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $2.51M 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | $2.51M 10-Q · filed 2026-05-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $2.04M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.04M 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $2.04M 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |